[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1121466T1 - Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης - Google Patents

Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης

Info

Publication number
CY1121466T1
CY1121466T1 CY20181100623T CY181100623T CY1121466T1 CY 1121466 T1 CY1121466 T1 CY 1121466T1 CY 20181100623 T CY20181100623 T CY 20181100623T CY 181100623 T CY181100623 T CY 181100623T CY 1121466 T1 CY1121466 T1 CY 1121466T1
Authority
CY
Cyprus
Prior art keywords
kallidine
des
arg10
antibodies
disclosure
Prior art date
Application number
CY20181100623T
Other languages
English (en)
Inventor
Dorothea Kominos
Jie Zhang
Alla PRITSKER
Matthew Davison
Nicolas Baurin
Govindan Subramanian
Xin Chen
Han Li
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49261064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121466(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi filed Critical Sanofi
Publication of CY1121466T1 publication Critical patent/CY1121466T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η αποκάλυψη παρέχει αντισώματα που δεσμεύονται ειδικά σε Καλλιδίνη ή des-Arg10-Καλλιδίνη. Η αποκάλυψη παρέχει επίσης φαρμακευτικές συνθέσεις, καθώς και νουκλεϊκά οξέα που κωδικοποιούν αντισώματα αντι-Καλλιδίνης ή des-Arg10-Καλλιδίνης, ανασυνδυασμένους φορείς έκφρασης και κύτταρα ξενιστές για την παρασκευή τέτοιων αντισωμάτων, ή θραυσμάτων αυτών. Μέθοδοι χρήσης αντισωμάτων της αποκάλυψης για τη διαμόρφωση της δραστικότητας Καλλιδίνης ή des-Arg10-Καλλιδίνης ή για την ανίχνευση της Καλλιδίνης ή des-Arg10-Καλλιδίνης ή, είτε in vitro είτε in vivo, παρέχονται επίσης από την αποκάλυψη. Η αποκάλυψη παρέχει περαιτέρω μεθόδους παρασκευής αντισωμάτων που δεσμεύονται ειδικά σε πεπτίδιο τύπου des-Argg-Βραδυκινίνης και des-Arg10-Καλλιδίνης.
CY20181100623T 2012-03-28 2018-06-14 Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης CY1121466T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616845P 2012-03-28 2012-03-28
FR1350953 2013-02-04
PCT/US2013/031836 WO2013148296A1 (en) 2012-03-28 2013-03-15 Antibodies to bradykinin b1 receptor ligands

Publications (1)

Publication Number Publication Date
CY1121466T1 true CY1121466T1 (el) 2020-05-29

Family

ID=49261064

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100623T CY1121466T1 (el) 2012-03-28 2018-06-14 Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης

Country Status (39)

Country Link
US (5) US9376494B2 (el)
EP (2) EP3246339B1 (el)
JP (4) JP6779012B2 (el)
KR (4) KR102035882B1 (el)
CN (2) CN113773385A (el)
AR (1) AR090352A1 (el)
AU (2) AU2013240242B2 (el)
BR (1) BR112014024282A2 (el)
CA (1) CA2868353C (el)
CL (2) CL2014002590A1 (el)
CO (1) CO7111293A2 (el)
CR (1) CR20140440A (el)
CY (1) CY1121466T1 (el)
DK (2) DK3246339T3 (el)
DO (1) DOP2014000199A (el)
EA (1) EA201491784A1 (el)
ES (1) ES2673869T3 (el)
GT (1) GT201400192A (el)
HK (1) HK1206754A1 (el)
HR (1) HRP20180928T1 (el)
HU (1) HUE037720T2 (el)
IL (1) IL234830B (el)
LT (1) LT2831113T (el)
MA (1) MA37407B1 (el)
MX (2) MX361874B (el)
MY (2) MY184037A (el)
NZ (1) NZ631543A (el)
PE (1) PE20142170A1 (el)
PH (1) PH12014501970A1 (el)
PL (1) PL2831113T3 (el)
PT (1) PT2831113T (el)
RS (1) RS57413B1 (el)
SG (2) SG10201702396QA (el)
SI (1) SI2831113T1 (el)
TR (1) TR201808486T4 (el)
TW (1) TWI605060B (el)
UA (1) UA117097C2 (el)
UY (1) UY34682A (el)
WO (1) WO2013148296A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201808486T4 (tr) * 2012-03-28 2018-07-23 Sanofi Sa Bradikinin B1 reseptör ligandlarına karşı antikorlar.
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
CN105504049B (zh) * 2014-09-26 2019-07-05 艾托金生物医药（苏州）有限公司 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用
CA3008621A1 (en) 2015-12-15 2017-06-22 Dyax Corp. Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
DK3452507T3 (da) 2016-05-02 2022-11-14 Prothena Biosciences Ltd Tau-immunoterapi
EP3452509A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
WO2017191560A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
PE20200695A1 (es) * 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
AU2018266711A1 (en) * 2017-05-08 2019-11-28 Adimab, Llc Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use
WO2019148186A1 (en) * 2018-01-29 2019-08-01 Silarus Therapeutics, Inc. Antibodies binding erfe and methods of use
PE20212324A1 (es) 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
EP0428534B1 (en) 1988-06-14 1995-03-29 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
ES2300113T3 (es) 1996-08-02 2008-06-01 Bristol-Myers Squibb Company Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo.
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
BRPI0314814C1 (pt) 2002-09-27 2021-07-27 Xencor Inc anticorpo compreendendo uma variante de fc
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2536408A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
CA2561264A1 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN101987870B (zh) 2004-07-15 2013-07-03 赞科股份有限公司 优化的Fc变体
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
KR20080015854A (ko) 2005-06-14 2008-02-20 사이토스 바이오테크놀로지 아게 항원 컨쥬게이트 및 그의 용도
US8460364B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
US8247537B2 (en) * 2006-11-15 2012-08-21 Medarex, Inc. Human monoclonal antibodies to BTLA and methods of use
WO2008151204A1 (en) 2007-06-04 2008-12-11 Sequent Medical Inc. Methods and devices for treatment of vascular defects
WO2008156622A1 (en) * 2007-06-12 2008-12-24 Ac Immune S.A. Humanized antibodies to amyloid beta
RU2015147300A (ru) 2007-08-29 2019-01-11 Санофи-Авентис Гуманизированные антитела к cxcr5, их производные и их применение
WO2009061996A2 (en) * 2007-11-07 2009-05-14 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
EP2420245A1 (en) * 2010-08-18 2012-02-22 Max-Delbrück-Centrum Für Molekulare Medizin Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
TR201808486T4 (tr) * 2012-03-28 2018-07-23 Sanofi Sa Bradikinin B1 reseptör ligandlarına karşı antikorlar.

Also Published As

Publication number Publication date
MA37407A1 (fr) 2016-05-31
CN113773385A (zh) 2021-12-10
JP2019050822A (ja) 2019-04-04
HRP20180928T1 (hr) 2018-07-27
SG11201405162YA (en) 2014-09-26
CO7111293A2 (es) 2014-11-10
JP2015513903A (ja) 2015-05-18
PL2831113T3 (pl) 2018-08-31
BR112014024282A2 (pt) 2017-08-08
HK1206754A1 (en) 2016-01-15
MY166157A (en) 2018-06-06
JP2024038036A (ja) 2024-03-19
TWI605060B (zh) 2017-11-11
AR090352A1 (es) 2014-11-05
JP7411609B2 (ja) 2024-01-11
KR20150002679A (ko) 2015-01-07
TR201808486T4 (tr) 2018-07-23
PE20142170A1 (es) 2015-01-07
ES2673869T3 (es) 2018-06-26
EP3246339B1 (en) 2019-10-09
DK3246339T3 (da) 2020-01-27
WO2013148296A1 (en) 2013-10-03
DOP2014000199A (es) 2014-10-31
US10465002B2 (en) 2019-11-05
KR102166083B1 (ko) 2020-10-16
KR20190121861A (ko) 2019-10-28
IL234830B (en) 2018-11-29
UA117097C2 (uk) 2018-06-25
US20230399388A1 (en) 2023-12-14
CN104334578B (zh) 2021-10-08
KR20220031728A (ko) 2022-03-11
KR20200121370A (ko) 2020-10-23
UY34682A (es) 2013-10-31
RS57413B1 (sr) 2018-09-28
SI2831113T1 (en) 2018-08-31
MY184037A (en) 2021-03-17
MX2014011688A (es) 2015-01-22
MA37407B1 (fr) 2018-03-30
US20200115441A1 (en) 2020-04-16
EP2831113B1 (en) 2018-03-14
HUE037720T2 (hu) 2018-09-28
CL2014002590A1 (es) 2015-01-16
CL2017003039A1 (es) 2018-03-16
US9879079B2 (en) 2018-01-30
CR20140440A (es) 2014-11-17
PH12014501970A1 (en) 2014-11-17
CN104334578A (zh) 2015-02-04
TW201343671A (zh) 2013-11-01
JP6779012B2 (ja) 2020-11-04
EP3246339A1 (en) 2017-11-22
SG10201702396QA (en) 2017-04-27
US9376494B2 (en) 2016-06-28
JP6912441B2 (ja) 2021-08-04
MX361874B (es) 2018-12-18
EP2831113A1 (en) 2015-02-04
CA2868353C (en) 2023-10-31
US20160368976A1 (en) 2016-12-22
MX2018015914A (es) 2021-12-08
US20180222967A1 (en) 2018-08-09
KR102035882B1 (ko) 2019-10-24
LT2831113T (lt) 2018-06-25
US20150050270A1 (en) 2015-02-19
PT2831113T (pt) 2018-06-20
EA201491784A1 (ru) 2015-02-27
JP2021166538A (ja) 2021-10-21
AU2013240242B2 (en) 2018-02-08
CA2868353A1 (en) 2013-10-03
NZ631543A (en) 2017-03-31
KR102367723B1 (ko) 2022-02-28
DK2831113T3 (en) 2018-06-25
AU2018203081A1 (en) 2018-05-24
AU2013240242A1 (en) 2014-10-02
GT201400192A (es) 2015-07-29

Similar Documents

Publication Publication Date Title
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1122824T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1123739T1 (el) Αντισωματα anti-cd38
CY1123355T1 (el) Αντισωματα εναντι cd73 και χρησεις εξ αυτων
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
EA201491644A1 (ru) Фармацевтические композиции
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
EA201890389A3 (ru) Композиции конъюгата xten и способы их получения
CY1117842T1 (el) Πολυπεπτιδια μεταλλαγμενης il-2
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
CY1119539T1 (el) Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
MX2015011830A (es) Metodos de fabricacion y sintesis de grupos de enlace de aminoacidos conjugados con compuestos usados para la obtencion de imagenes dirigida de los tumores.
UY32971A (es) Proteínas de unión al antígeno de la il-23 humana
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
EA201991409A3 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA201590705A1 (ru) ПОЛУЧЕНИЕ РЕКОМБИНАНТНОЙ ВАКЦИНЫ В E.coli ПОСРЕДСТВОМ ЭНЗИМАТИЧЕСКОЙ КОНЪЮГАЦИИ
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
AR080680A1 (es) Proteinas de union a basigina